

Appl. No. : 10/630,629
Filed : July 29, 2003

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising P. falciparum erythrocyte binding protein-2 (EBP2) Region II (RII), the amino acid sequence of which is amino acids 147 to 762 of SEQ ID NO:1 a parologue of EBA-175 polypeptide sequence.
2. (Currently amended) The pharmaceutical composition of Claim 1, wherein the polypeptide comprises P. falciparum erythrocyte binding protein-2 (EBP2), the amino acid sequence of which is parologue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.
3. (Original) The pharmaceutical composition of Claim 1, further comprising an isolated sialic acid binding protein (SABP) binding domain polypeptide in an amount sufficient to induce a protective immune response to *Plasmodium falciparum* merozoites in a mammal.
4. (Currently amended) An isolated polypeptide comprising P. falciparum erythrocyte binding protein-2 (EBP2) Region II (RII), the amino acid sequence of which is amino acids 147 to 762 of SEQ ID NO:1 a parologue of EBA-175 polypeptide sequence.
5. (Currently amended) The isolated polypeptide of Claim 4, wherein the polypeptide comprises P. falciparum erythrocyte binding protein-2 (EBP2), the amino acid sequence of which is parologue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.
6. (Withdrawn) An isolated nucleic acid sequence comprising a parologue of EBA-175 nucleic acid sequence.
7. (Withdrawn) The isolated nucleic acid sequence of Claim 6, wherein the parologue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.
8. (Withdrawn) A vector comprising a parologue of EBA-175 nucleic acid sequence.
9. (Withdrawn) The vector of Claim 8, wherein the parologue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.
10. (Withdrawn) A recombinant host cell comprising a parologue of EBA-175 nucleic acid sequence.
11. (Withdrawn) The recombinant host cell of Claim 10, wherein the parologue of EBA-175 nucleic acid sequence comprises the sequence of SEQ ID NO:1.

Appl. No. : 10/630,629
Filed : July 29, 2003

12. (Withdrawn) A recombinant host cell comprising the vector of Claim 8.
13. (Withdrawn and Currently amended) A method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of the pharmaceutical composition of Claim 1 a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated polypeptide comprising a parologue of EBA-175 polypeptide sequence.
14. (Withdrawn and Currently amended) A The method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of the pharmaceutical composition of Claim 2 of Claim 13, wherein the parologue of EBA-175 polypeptide sequence is encoded by the sequence of SEQ ID NO:1.
15. (Withdrawn and Currently amended) A The method for an immune response to *Plasmodium falciparum* merozoites in a patient, the method comprising administration to the patient of an immunologically effective amount of the pharmaceutical composition of Claim 3 of claim 14, further comprising administration to the patient of an immunologically effective amount of an isolated SABP binding domain polypeptide.
16. (Withdrawn) A recombinant method for making a parologue of EBA-175 polypeptide, comprising:
 - expressing the vector of claim 8 in a host cell; and
 - isolating the parologue of EBA-175 polypeptide from said host cell.
17. (Withdrawn) An isolated antibody, wherein the antibody binds a 5' cysteine rich region of an EBA-175 protein parologue from a *Plasmodium* species.
18. (Withdrawn) The isolated antibody of Claim 17, wherein the 5' cysteine rich region is a region II.
19. (Withdrawn) The isolated antibody of Claim 18, wherein the 5' cysteine rich region is a region II/F2.
20. (Withdrawn) The isolated antibody of Claim 17, wherein the antibody inhibits binding of an EBA-175 protein to a red blood cell.